Financial Performance Highlights

Quarterly Performance (Q2 FY27 vs Q2 FY26)

  • Revenue from operations: ₹9,879 million (up 16.2% from ₹8,503 million)
  • EBITDA before ESOP costs: ₹2,077 million (up 10.3% from ₹1,883 million)
  • EBITDA margin: 21.0% (down from 22.1%)
  • Profit after tax (PAT): ₹847 million (up 16.1% from ₹729 million)

Quarterly Performance (Q2 FY27 vs Q1 FY27)

  • Revenue from operations: ₹9,879 million (up 4.4% from ₹9,464 million)
  • EBITDA before ESOP costs: ₹2,077 million (up 1.5% from ₹2,047 million)
  • EBITDA margin: 21.0% (down from 21.6%)
  • Profit after tax (PAT): ₹847 million (up 6.8% from ₹793 million)

Half-Yearly Performance (H1 FY27 vs H1 FY26)

  • Revenue from operations: ₹19,343 million (up 17.8% from ₹16,419 million)
  • EBITDA before ESOP costs: ₹4,124 million (up 29.9% from ₹3,176 million)
  • EBITDA margin: 21.3% (up from 19.3%)
  • Profit after tax (PAT): ₹1,639 million (up 49.4% from ₹1,098 million)

Management Commentary

Dr Hari Babu Bodepudi, Managing Director and Group CEO, stated that the company delivered "stellar quarter" performance with H1 revenue up 17.8% and H1 PAT at ₹164 crore (₹1,639 million), up approximately 50% from last year. The company reported H1 adjusted PAT with normalized ESOP cost of ₹204 crore (assuming normalized annual ESOP cost of ₹25 crore).

Strategic Developments

The company completed the acquisition of BioForLife in Italy, which strengthens its companion animal platform. Viyash Scientific is also investing in new oncology capabilities, in-house companion animal manufacturing facility, and expanding API capacity to meet customer demand. The management emphasized focus on disciplined execution, R&D-led growth, and sustainable value creation.

Operational Overview

Viyash Scientific is an integrated pharmaceutical company with businesses across Formulations, APIs and CDMO services for Human and Animal Health. The company operates 16 manufacturing facilities with R&D, manufacturing and distribution operations across India, Spain, Brazil, Turkey, and the USA. It has approvals from international regulators including USFDA, EU GMP, WHO and TGA.

Key operational metrics:

  • 110+ APIs
  • 30+ human health formulations
  • 140+ animal health formulations
  • Serves customers in 150+ countries
  • 3,300+ employees
  • 335+ scientists
  • 190+ patents filed
  • 1,000+ registrations

Investor Communication

The company will hold an earnings call at 11:00 AM IST on November 14, 2026, where management will discuss the company's performance and take questions from participants. Dial-in numbers: +91 22 6280 1263 or +91 22 7115 8213.

Safe Harbor Statement

The document contains forward-looking statements subject to risks and uncertainties including government actions, local, political or economic developments, technological risks, and other factors that could cause actual results to differ materially. The company undertakes no obligation to publicly update these statements.